SELLAS Life Sciences Stock Drops 14% Weekly Ahead of ASH Conference
SELLAS Life Sciences Group, Inc. (SLS) closed nearly 12% lower at $9.98 on Friday, extending a three-session decline and ending the week down 14%. The slide marked the worst weekly performance in over a month for the biotechnology company, though shares remain up 165% year-to-date.
Investor attention has shifted toward the upcoming American Society of Hematology annual meeting in New Orleans, where Sellas has secured exhibit space. Market participants are anticipating potential updates on Galinpepimut-S, the company's immunotherapy candidate in Phase 3 testing for acute myeloid leukemia. The Regal trial requires 80 events to trigger a final analysis, with 78 events recorded at the last update. Abstract releases for the conference are governed by embargo policies set for Nov. 4 and Dec. 7.
Looking ahead, Sellas also plans to disclose fourth-quarter topline results from an 80-patient Phase 2 trial of SLS009 in acute myeloid leukemia. Preclinical laboratory studies have also demonstrated activity for SLS009 when combined with Daraxonrasib in resistant pancreatic cancer models.
Key points
- SELLAS Life Sciences Group, Inc. (SLS) stock fell 11.99% on Friday to $9.98, logging a 14% weekly loss.
- Investors are watching the upcoming ASH conference in New Orleans for updates on the Phase 3 Regal study.
- The Phase 3 Regal trial requires 80 events to trigger its final analysis, with 78 previously reported.
- Sellas expects fourth-quarter Phase 2 topline results for SLS009 in acute myeloid leukemia.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Why did Sellas Life Sciences stock drop on Friday?
Sellas Life Sciences stock fell 11.99% on Friday to $9.98, completing a three-session losing streak and a 14% weekly decline, marking its worst week in over a month.
What is the main clinical trial milestone Sellas investors are watching?
Investors are monitoring the Phase 3 Regal trial evaluating Galinpepimut-S in acute myeloid leukemia, which requires 80 death events to trigger its final analysis after reaching 78 at its last disclosure.
When will trial results be unembargoed for the ASH conference?
Abstract data for the American Society of Hematology conference remains under embargo until Nov. 4 for regular abstracts and Dec. 7 for late-breaking submissions.